Powered by

Amphivena Expands Executive Team

Mar 05, 2019 - Business Wire
Board and Executive Moves

Amphivena Therapeutics, Inc., a privately held clinical stage immuno-oncology (I/O) company that develops T cell engager therapeutics for myeloid malignancies and solid tumors, announced today the appointment of Victoria Smith, Ph.D. to the position of Chief Scientific Officer. Separately, the company said that Peter Van Vlasselaer, Ph.D. joined the Amphivena Board of Directors as an independent Executive Chairman.

"Drs. Smith and Van Vlasselaer bring strong leadership in immuno-oncology a...